Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Mesoblast Limited (MESO)

3.61   -0.06 (-1.63%) 12-05 16:00
Open: 3.89 Pre. Close: 3.67
High: 3.94 Low: 3.56
Volume: 275,952 Market Cap: 532(M)

Technical analysis

as of: 2022-12-06 7:49:43 AM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 4.6     One year: 5.37
Support: Support1: 3.21    Support2: 2.75
Resistance: Resistance1: 3.94    Resistance2: 4.6
Pivot: 3.33
Moving Average: MA(5): 3.57     MA(20): 3.25
MA(100): 3.11     MA(250): 3.56
MACD: MACD(12,26): 0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 80.2     %D(3): 85.6
RSI: RSI(14): 64.4
52-week: High: 6.13  Low: 2.14
Average Vol(K): 3-Month: 77 (K)  10-Days: 123 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ MESO ] has closed below upper band by 17.9%. Bollinger Bands are 27.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.94 - 3.98 3.98 - 4
Low: 3.5 - 3.53 3.53 - 3.55
Close: 3.57 - 3.62 3.62 - 3.65

Company Description

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and GrĂ¼nenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Headline News

Tue, 06 Dec 2022
Siyo to lead SA U19 women at inaugural ICC T20 World Cup - SuperSport

Tue, 06 Dec 2022
Global Mesotherapy Market 2023 Size and Emerging Trends that Value Expected to Reach USD 634.82 Mn | Growing at CAGR of 32.1% | Forecast to 2027 - Digital Journal

Sun, 04 Dec 2022
MESO Makers Winter Market at Alberta Commons – Events - The Columbian

Sun, 04 Dec 2022
After the Racetrack: Mr. Meso - Twinspires Edge

Tue, 29 Nov 2022
Assessment of Mesothelioma Symptoms More Accurate With Mixed-Methods Approach - Oncology Nurse Advisor

Wed, 23 Nov 2022
Health Care Sector Update for 11/23/2022: MESO, XERS, HZNP, AZTA, XLV, IBB - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 147 (M)
Shares Float 132 (M)
% Held by Insiders 0 (%)
% Held by Institutions 2.9 (%)
Shares Short 539 (K)
Shares Short P.Month 516 (K)

Stock Financials

EPS -0.71
EPS Est Next Qtl -0.25
EPS Est This Year -0.77
EPS Est Next Year -0.42
Book Value (p.s.) 3.82
Profit Margin (%) 0
Operating Margin (%) -789.1
Return on Assets (ttm) -7.2
Return on Equity (ttm) -17
Qtrly Rev. Growth 12.6
Gross Profit (p.s.) -0.37
Sales Per Share 0.06
EBITDA (p.s.) -0.53
Qtrly Earnings Growth 0
Operating Cash Flow -66 (M)
Levered Free Cash Flow -44 (M)

Stock Valuations

PE Ratio -5.09
PEG Ratio -0.2
Price to Book value 0.94
Price to Sales 52.08
Price to Cash Flow -8.09

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.